Melissa Kelley
Adult Health · Venice, FLNPI 1528517562
Payments from drug & device makers
Across 316 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$1K
- Lilly USA, LLC$859
- Exact Sciences$525
- GSK$451
- Amgen$383
- plus $2K from 24 others
What the payments were for
- Travel & lodging$100%
- Food & beverage$6,23297%
- Education$1843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $1,115 |
| Pfizer | 52 | $1,006 |
| Lilly USA, LLC | 53 | $859 |
| Exact Sciences | 18 | $525 |
| GSK | 35 | $451 |
| Amgen(2 entities) | 23 | $383 |
| Astellas Pharma US Inc | 9 | $335 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $252 |
| Bayer | 9 | $237 |
| Boston Scientific | 4 | $205 |
| AstraZeneca | 8 | $183 |
| Novo Nordisk | 8 | $171 |
| Centinel Spine, LLC | 1 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $75 |
| Cvrx, Inc. | 2 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $49 |
| Mylan Specialty L.p. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $34 |
| Novartis | 2 | $31 |
| Radius Health, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| Abbott | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRODISC C VIVO$155
- WATCHMAN FLX$144
How this compares
$6,426 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $122,355 |
| MounjaroTirzepatide | 59 | $90,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $65,992 |
| XareltoRivaroxaban | 44 | $54,641 |
| OzempicSemaglutide | 42 | $45,322 |
| JardianceEmpagliflozin | 38 | $41,842 |
| FarxigaDapagliflozin Propanediol | 19 | $25,997 |
| Repatha SureclickEvolocumab | 18 | $19,995 |
| ProliaDenosumab | 11 | $19,047 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $11,345 |
| Rosuvastatin Calcium | 496 | $6,373 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,149 |
| Levothyroxine Sodium | 375 | $3,352 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $3,146 |
| Atorvastatin Calcium | 360 | $2,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,006 | $122,35597 claims |
| Lilly USA, LLCMounjaro | $859 | $90,81259 claims |
| GSKTrelegy Ellipta | $451 | $65,99259 claims |
| Novo NordiskOzempic | $171 | $45,32242 claims |
| Boehringer IngelheimJardiance | $38 | $41,84238 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $183 | $37,34331 claims |
| AmgenProlia | $383 | $19,04711 claims |
| AbbVieSynthroid | $1,115 | $2,63045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Venice
- Sherry RogersVenice$20K
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.